GlassScriptPhysician profile
Stella Bo Sun Kyung
NPI 1184034878
$1,517.65
in general payments reported to CMS, 2019-2025
16 companies · $161 in 2025
The $161 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $140 · 2020: $175 · 2022: $253 · 2023: $397 · 2024: $392 · 2025: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $950.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $950.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $239.35 | 2019-2023 | Watchman Access System |
| Novartis Pharmaceuticals Corporation | $202.37 | 2022-2025 | |
| Edwards Lifesciences Corporation | $192.30 | 2020-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Impulse Dynamics (USA) INC. | $119.84 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $116.53 | 2022-2024 | Farxiga |
| Scpharmaceuticals INC. | $116.31 | 2024-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $113.94 | 2022-2024 | Lifevest |
| Heartflow, INC. | $113.32 | 2024 | |
| Janssen Pharmaceuticals, INC | $98.66 | 2022-2023 | Xarelto |
| Abbott Laboratories | $56.24 | 2024-2025 | Cardiomems |
| Amgen INC. | $45.36 | 2022-2023 | Repatha |
| Pfizer INC. | $36.30 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $17.80 | 2023 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.14 | 2023 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $16.45 | 2025 | Eliquis |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $15.74 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stella Kyung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.